Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NoVa
NCT06464510Phase 3Recruiting
- Sponsor
- HCor
- Start
- Nov 2024
- Primary completion
- Aug 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vasopressin in septic shock (2 arms), sponsored by HCor. Primary endpoint: All-cause mortality or renal replacement therapy at 28 days. Started Nov 2024; status: recruiting.
02
Drugs
vasopressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT06464510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06464510.